Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | BeOne Medicines

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Beigene Study ID

BGB-3111-205

ClinicalTrials.gov ID

NCT03206918

China Drug Trials ID

CTR20160890

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan